SCHEMBL3728027

SCHEMBL3728027

NCC(CC(N)=O)S(=O)(=O)O

nearest known ligand 0.39

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GABRR1 P24046 2/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28012880 0.87 KDM4E (0.32) LMNA
SCHEMBL1119824 0.81 LMNA (0.46) GABRR1LMNA
SCHEMBL7568558 0.79 ALDH1A1 (0.39) GABRR1LMNA
SCHEMBL13192615 0.79 CYP1A2 (0.30) GABRR1LMNA
SCHEMBL27959803 0.79
SCHEMBL18930093 0.74 MGAM (0.38) LMNA
SCHEMBL3980744 0.74 ALDH1A1 (0.33)
SCHEMBL4078147 0.74
SCHEMBL27665160 0.73 CA2 (0.42)
SCHEMBL18930173 0.71 CYP1A2 (0.41) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024041544-A9 A METHOD OF PREPARING AN ANTIBODY WITH SITE-SPECIFIC MODIFICATIONS SUZHOU BIOREINNO BIOTECHNOLOGY LIMITED COMPANY (CN) 2025-01-30 WO disclosed
WO-2024041542-A1 A METHOD FOR PROGRAMMATICALLY MANAGING ANTIBODY DISULFIDE BONDS SITE-SPECIFIC MODIFICATION SUZHOU BIOREINNO BIOTECHNOLOGY LIMITED COMPANY (CN) 2024-02-29 WO disclosed
WO-2024041541-A1 A NOVEL THIOL REDUCTANT, METHOD AND USE THEREOF SUZHOU BIOREINNO BIOTECHNOLOGY LIMITED COMPANY (CN) 2024-02-29 WO disclosed
WO-2024044520-A1 BIOCOMPATIBLE PARAHYDROGEN HYPERPOLARIZED SOLUTIONS BY PRECIPITATION AND RE-DISSOLUTION NORTH CAROLINA STATE UNIVERSITY (US) 2024-02-29 WO disclosed
WO-2024041543-A1 A METHOD OF PREPARING AN ANTIBODY WITH THIOL GROUP SITE-SPECIFIC MODIFICATIONS AND USE OF TCEP SUZHOU BIOREINNO BIOTECHNOLOGY LIMITED COMPANY (CN) 2024-02-29 WO disclosed
WO-2024041544-A1 A METHOD OF PREPARING AN ANTIBODY WITH SITE-SPECIFIC MODIFICATIONS SUZHOU BIOREINNO BIOTECHNOLOGY LIMITED COMPANY (CN) 2024-02-29 WO disclosed
WO-2024041545-A1 A NOVEL THIOL REDUCTANT, PREPARATION METHOD AND USE THEREOF SUZHOU BIOREINNO BIOTECHNOLOGY LIMITED COMPANY (CN) 2024-02-29 WO disclosed
EP-2173169-A1 NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS CyDex Pharmaceuticals, Inc. (US) 2010-04-14 EP disclosed
WO-2009003199-A1 NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS CYDEX PHARMACEUTICALS, INC. (US) 2008-12-31 WO disclosed
EP-1687337-A1 A METHOD FOR THE TREATMENT OF MALIGNANT DISEASES BY INHIBITING NUCLEOLIN University of Louisville Research Foundation (US) 2006-08-09 EP disclosed
WO-2005035579-A1 A METHOD FOR THE TREATMENT OF MALIGANT DISEASES BY INHIBITING NUCLEOLIN UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2005-04-21 WO disclosed
EP-1255576-A1 MINERAL-POLYMER HYBRID COMPOSITION Biosyntech Canada Inc. (CA) 2002-11-13 EP disclosed
WO-2001041822-A1 MINERAL-POLYMER HYBRID COMPOSITION BIOSYNTECH CANADA INC. (CA) 2001-06-14 WO disclosed
US-6048390-A DYE HAVING AT LEAST ONE CARBOXYL GROUP IN THE FORM OF A FREE ACID; A SECONDARY OR TERTIARY AMINE; ALKALI METAL HYDROXIDE FUJI XEROX CO., LTD. (JP) 2000-04-11 US disclosed